The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Several lines of evidences have suggested that T cell activation could be impaired in the tumor environment, a condition referred to as tumor-induced immunosuppression. We have previously shown that tenascin-C, an extracellular matrix protein highly expressed in the tumor stroma, inhibits T lymphocyte activation in vitro, raising the possibility that this molecule might contribute to tumor-induced immunosuppression in vivo. However, the region of the protein mediating this effect has remained elusive. Here we report the identification of the minimal region of tenascin-C that can inhibit T cell activation. Recombinant fragments corresponding to defined regions of the molecule were tested for their ability to inhibit in vitro activation of human peripheral blood T cells induced by anti-CD3 mAbs in combination with fibronectin or IL-2. A recombinant protein encompassing the alternatively spliced fibronectin type III domains of tenascin-C (TnFnIII A–D) vigorously inhibited both early and late lymphocyte activation events including activation-induced TCR/CD8 down-modulation, cytokine production, and DNA synthesis. In agreement with this, full length recombinant tenascin-C containing the alternatively spliced region suppressed T cell activation, whereas tenascin-C lacking this region did not. Using a series of smaller fragments and deletion mutants issued from this region, we have identified the TnFnIII A1A2 domain as the minimal region suppressing T cell activation. Single TnFnIII A1 or A2 domains were no longer inhibitory, while maximal inhibition required the presence of the TnFnIII A3 domain. Altogether, these data demonstrate that the TnFnIII A1A2 domain mediate the ability of tenascin-C to inhibit in vitro T cell activation and provide insights into the immunosuppressive activity of tenascin-C in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of tenascin in healing wounds
Mackie, E. J., Halfter, W., & Liverani, D. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.6.2757 · Cited by 555 · cited 1×
“Highly increased tenascin-C deposition is found at sites of angiogenesis, in healing wounds and in the stroma of malignant tumors (23), including breast (16), glioma (24), melanoma (25), endometrial adenocarcinoma (26), ovarian cancers (27), and Hodgkin’s lymphoma (28).”
BackgroundTwo contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments
Spring, J., Beck, K., & Chiquet-Ehrismann, R. (1989) · Cell · doi:10.1016/0092-8674(89)90294-8 · Cited by 413 · cited 1×
“For example, the EGF type repeats prevent adhesion of L929 mouse fibroblasts (33) and induce neurite outgrowth (34).”
Background
Cited by
Function of alternative splicing
Stamm, S., Ben-Ari, S., Rafalska, I., Tang, Y., Zhang, Z., Toiber, D., Thanaraj, T. A., & Soreq, H. (2005) · Gene · doi:10.1016/j.gene.2004.10.022 · Cited by 1,377
Aberrant and Alternative Splicing in Cancer
Venables, J. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1910 · Cited by 634
The role of tenascin-C in tissue injury and tumorigenesis
Midwood, K. S., & Orend, G. (2009) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-009-0075-1 · Cited by 438
Tenascin-C induced signaling in cancer
Orend, G., & Chiquet-Ehrismann, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.02.017 · Cited by 384
Huang, J., Heng, S., Zhang, W., Liu, Y., Xia, T., Ji, C., & Zhang, L.-J. (2022) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.02.027 · Cited by 238
Metadata
- Authors
- Puente Navazo, M. D., Valmori, D., & Rüegg, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-12-01
- Volume
- 167
- Issue
- 11
- Pages
- 6431-6440
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2164787467
- Cited by
- 54
- References
- 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.